Childbirth monitoring technology has barely changed since the 1960s

VitalTrace has had the pleasure of participating in iPREP WA's Industry and PhD Research and Engagement Program. We were fortunate to work with our very own “Dream Team”; Alvin Lee, Saman Akbar Zadeh and Georgios Mavropalias, bringing their expertise in signal processing, data science and biomedical science respectively.

VitalTrace was founded to improve the safety for mothers and babies during childbirth - babies being some of our youngest and most vulnerable patients. We are passionate about eliminating the unnecessary health, psychological and economic burdens from inaccurate childbirth monitoring.

This project will progress development and clinical testing of a continuous lactate sensor, with the potential to revolutionise fetal monitoring during labour globally.

Current fetal monitoring technology is inaccurate, subjective and creates difficulties for clinicians leading to complications for mothers and babies. VitalTrace is developing DelivAssureTM, a breakthrough technology designed to continuously monitor clinically validated biomarkers to reduce fetal morbidities and wirelessly transmit readings to an associated display monitor.

The funding awarded through the Clinical Translation and Commercialisation Medtech grant, will help design and run VitalTrace's first clinical trial, testing DelivAssureTM, a novel continuous lactate biosensor, which has already received Breakthrough Device designation from the US FDA.

From Prof. Jonathan Morris, VitalTrace - Chief Medical Officer

I had the wonderful opportunity to present VitalTrace’s pre-clinical data in the highly regarded Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting in Denver, Colorado. This is the premier pregnancy meeting in USA. Our abstract was one of the 104 selected for presentation out of more than 2,000 submitted speaking to the significance and magnitude of the accomplishments we have achieved.

SMFM was a great opportunity to connect with obstetricians allowing VitalTrace to build invaluable relationships with leading practitioners and forming alliances to prepare the company for future activity in the United States and beyond. There was very strong interest in DelivAssure from leaders in Boston, Washington, Texas, East Virginia, New York and Philadelphia amongst others.

Some particularly notable feedback:

From Dr Emily Reiff (Brigham and Women’s Hospital, Harvard Medical School),

“I was fascinated by your study of real-time fetal lactate monitoring and think that innovation like this is what is needed for effective intrapartum management.”
‍

From Dr Justin Lappen (Cleveland Clinic),

“The whole team thought that DelivAssure would assist with Class II CTG dilemmas.”

‍

It was reinvigorating to see such strong support for continuous lactate monitoring and reinforces our confidence to launch DelivAssure in the United States.